MedTrace Logo

A Pilot Study of [Ga-68]PSMA PET/MRI for the Assessment of PSMA-positive Tumors

NCT02978586 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 8

Last updated 2021-05-07

No results posted yet for this study

Summary

The purpose of this study is to see if positron emission tomography/ magnetic resonance imaging (PET/MRI) can be used to monitor the effectiveness of cancer treatment using an investigational radioactive drug called \[Ga-68\]PSMA.

Conditions

Interventions

DEVICE

[Ga-68]PSMA PET/MR

All participants will undergo at least 1 baseline \[Ga-68\]PSMA PET/MR. If participants test positive for \[Ga-68\]PSMA tumor uptake, they will under up to 2 additional scans

Sponsors & Collaborators

  • Case Comprehensive Cancer Center

    lead OTHER

Principal Investigators

  • Norbert Avril, MD · University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-14
Primary Completion
2019-10-25
Completion
2019-10-25
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02978586 on ClinicalTrials.gov